Choose a date range

From To

Choose one or more categories


Show only original CenterWatch stories


inVentiv Health expands global regulatory, compliance services for non-interventional studies

Friday, May 15, 2015 02:27 PM

Global CRO inVentiv Health has expanded its compliance products and services to assist biopharmaceutical companies conducting non-interventional studies (NIS) around the world. Clients of the new services will have access to an NIS Regulatory Intelligence Database, the first of its kind.

More... »

Quest Diagnostics

Denali Therapeutics launches to study neurodegenerative disease treatments

Friday, May 15, 2015 02:23 PM

Denali Therapeutics, a new California-based biotechnology company focused on developing effective therapies for neurodegenerative diseases, has launched with an initial investment commitment of $217 million. Denali is based on the collaboration of world-class scientists, industry experts and investors. Recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines for Alzheimer's disease, Parkinson's disease, ALS and other neurodegenerative diseases.

More... »

WuXi PharmaTech forms special committee to evaluate non-binding proposal

Friday, May 15, 2015 02:22 PM

Global CRO WuXi PharmaTech has announced that, in response to a preliminary non-binding proposal letter, dated April 29, received by the company's board of directors from Dr. Ge Li, founder, chairman and CEO of the company, and Ally Bridge Group Capital Partners to acquire the company in a "going private" transaction, the board has formed a special committee of independent directors consisting of Xuesong (Jeff) Leng, William R. Keller and Walter T. Kwauk to evaluate the proposed transaction.  

More... »

California Life Sciences Association launches, following BayBio, California Healthcare Institute merger

Friday, May 15, 2015 02:18 PM

The California Life Sciences Association (CLSA) has officially launched as a representation for California’s life sciences sector. CLSA now is the largest state and regional life sciences advocacy group in the country, with more than 750 members. The organization advances California’s life sciences innovation ecosystem by advocating for effective national, state and local public policies and supporting entrepreneurs and life sciences businesses. CLSA is the result of a completed merger between BayBio and California Healthcare Institute.

More... »

Department of Defense, AcelRx partner to advance ARX-04

Friday, May 15, 2015 02:17 PM

AcelRx Pharmaceuticals, a Redwood City, Calif.-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, has entered into a contract worth up to $17 million supported by the U.S. Army Medical Research and Materiel Command (USAMRMC) within the U.S. Department of Defense (DoD).

More... »

Eli Lilly, Sanford-Burnham collaborate to investigate immunological therapies

Friday, May 15, 2015 02:15 PM

Eli Lilly and Sanford-Burnham Medical Research Institute, a nonprofit medical research institute based in Florida, are collaborating to discover and develop immunological therapies. The company will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders.

More... »

The Center for Drug R&D, IRICoR partner

Thursday, May 14, 2015 01:20 PM

The Institute for Research in Immunology and Cancer—Commercialization of Research (IRICoR) at the Université de Montréal (UdeM) and the Center for Drug R&D (CDRD) have initiated collaborations on three new drug development projects. These projects, which address areas of high unmet medical need, are being supported by funding from Merck & Co. to IRICoR.

More... »

Sanofi, Selecta Biosciences extend partnership on synthetic vaccine particle technology

Thursday, May 14, 2015 01:18 PM

Sanofi, in relation to an existing collaboration, has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease with Selecta Biosciences, a Watertown, Mass.-based clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies.

More... »

QPS opens in vitro dermal, transdermal research laboratory in North Dakota

Thursday, May 14, 2015 01:16 PM

QPS Holdings, a full-service CRO, has opened a new in vitro dermatology and transdermal research laboratory in Fargo, N.D. This new physical extension of QPS’ dermal and transdermal research services portfolio will further strengthen QPS’ ability to assist clients in quickly moving their dermal and transdermal products from preclinical evaluations through to late stage clinical development.

More... »

Theorem opens clinical supplies facility in Germany

Thursday, May 14, 2015 01:15 PM

King of Prussia, Pa-based CRO Theorem Clinical Research will open a new state-of-the-art clinical supplies facility in Frankfurt, Germany, in June.

More... »


May 18

Research for All Act reaches Congress for second time seeking gender equality in basic research, clinical trials

MediciGlobal finds fewer trial dropouts among participants who actively pursue enrollment versus those recruited

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Job satisfaction mixed as workload increases
Salaries not keeping pace with rise in work, responsibilities

Gamification moving from early science to patient use
Pharma looking to use games for early diagnosis, recruitment, adherence

Already a subscriber?
Log in to your digital subscription.

Purchase the May issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs